Ashton Thomas Private Wealth LLC Sells 3,331 Shares of Cencora, Inc. (NYSE:COR)

Ashton Thomas Private Wealth LLC trimmed its stake in shares of Cencora, Inc. (NYSE:COR) by 41.6% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,667 shares of the company’s stock after selling 3,331 shares during the quarter. Ashton Thomas Private Wealth LLC’s holdings in Cencora were worth $1,134,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently made changes to their positions in the stock. Vanguard Group Inc. bought a new stake in shares of Cencora during the fourth quarter valued at approximately $4,212,508,000. Sumitomo Mitsui Trust Holdings Inc. bought a new stake in shares of Cencora during the first quarter valued at approximately $238,457,000. Wealth Enhancement Advisory Services LLC bought a new stake in shares of Cencora during the first quarter valued at approximately $66,911,000. PNC Financial Services Group Inc. bought a new stake in shares of Cencora during the fourth quarter valued at approximately $51,339,000. Finally, Allspring Global Investments Holdings LLC bought a new stake in shares of Cencora during the first quarter valued at approximately $50,337,000. 97.52% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Cencora

In other Cencora news, COO Robert P. Mauch sold 57,564 shares of the business’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $235.09, for a total value of $13,532,720.76. Following the sale, the chief operating officer now directly owns 24,412 shares in the company, valued at $5,739,017.08. The sale was disclosed in a filing with the SEC, which is accessible through this link. In related news, Director Dermot Mark Durcan acquired 500 shares of the firm’s stock in a transaction that occurred on Friday, May 24th. The shares were bought at an average cost of $218.58 per share, for a total transaction of $109,290.00. Following the purchase, the director now owns 21,876 shares in the company, valued at approximately $4,781,656.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Robert P. Mauch sold 57,564 shares of the business’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $235.09, for a total value of $13,532,720.76. Following the sale, the chief operating officer now owns 24,412 shares in the company, valued at $5,739,017.08. The disclosure for this sale can be found here. Insiders have sold a total of 1,956,675 shares of company stock worth $422,352,056 over the last ninety days. 15.80% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the company. Citigroup lifted their target price on Cencora from $265.00 to $280.00 and gave the company a “buy” rating in a research report on Tuesday, April 30th. Robert W. Baird lifted their target price on Cencora from $275.00 to $277.00 and gave the company an “outperform” rating in a research report on Thursday, May 2nd. SVB Leerink reaffirmed an “outperform” rating and set a $275.00 target price on shares of Cencora in a research report on Thursday, June 27th. Finally, StockNews.com cut Cencora from a “strong-buy” rating to a “buy” rating in a research report on Thursday, May 2nd. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $235.30.

Cencora Stock Performance

COR stock traded down $1.92 during midday trading on Friday, hitting $220.58. The company’s stock had a trading volume of 134,091 shares, compared to its average volume of 1,394,149. The stock’s 50-day moving average price is $227.90 and its 200 day moving average price is $228.39. The company has a quick ratio of 0.53, a current ratio of 0.89 and a debt-to-equity ratio of 3.41. Cencora, Inc. has a 1 year low of $171.65 and a 1 year high of $246.75. The stock has a market cap of $43.99 billion, a price-to-earnings ratio of 24.34, a PEG ratio of 1.55 and a beta of 0.45.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, May 1st. The company reported $3.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.65 by $0.15. The firm had revenue of $68.41 billion for the quarter, compared to analyst estimates of $70.60 billion. Cencora had a return on equity of 268.67% and a net margin of 0.67%. The business’s revenue was up 7.8% on a year-over-year basis. During the same period in the previous year, the company posted $3.50 earnings per share. On average, equities analysts forecast that Cencora, Inc. will post 13.44 EPS for the current year.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, May 24th. Shareholders of record on Friday, May 10th were paid a $0.51 dividend. The ex-dividend date of this dividend was Thursday, May 9th. This represents a $2.04 annualized dividend and a dividend yield of 0.92%. Cencora’s payout ratio is presently 22.32%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.